Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.97 |
| ▸ | NPC1 | O15118 | 7/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27267057 | 0.98 | RAB9A (1.00) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL27264917 | 0.98 | RAB9A (1.00) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL16866144 | 0.94 | NPC1 (0.86) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL23573491 | 0.88 | NPC1 (0.77) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL8777821 | 0.88 | RAB9A (0.77) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL23573490 | 0.88 | NPC1 (0.77) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL4983290 | 0.85 | L3MBTL1 (0.76) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL9273863 | 0.84 | NPC1 (0.70) | RAB9ANPC1POLBL3MBTL1EPHX2 | |
| SCHEMBL2752049 | 0.82 | NPC1 (0.68) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL2752715 | 0.81 | RAB9A (0.97) | RAB9ANPC1POLBEPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178570-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20060293342-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| CN-1021819-C | PROCESS FOR DIUREA DERIVATIVES USEFUL AS MEDICAMENTS | YAMANOUCHI PHARMA CO LTD (JP) | 1993-08-18 | — | — | CN | disclosed |
| CN-1034538-A | As useful diurea derivatives of medicine and preparation method thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1989-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293342-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | RAB9A 3880/4885NPC1 4467/4885POLB 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.